Please Login to participate

Course HomeCourse Progress
  • Pre-Test
  • Access Webinar
  • Evaluation
  • Certificate

PI3K Inhibitors in the Treatment of Non-Hodgkin Lymphomas


Richard Furman, MD
Professor of Medicine
New York Presbyterian Hospital
Weill Cornell Medicine
New York, New York

Alex Herrera, MD
Assistant Professor
City of Hope Medical Center
Duarte, California

Caron A. Jacobson, MD, MMSc
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Manali Kamdar, MD
Associate Professor
University of Colorado
Aurora, Colorado

Nicole Lamanna, MD
Associate Professor, Leukemia
Columbia University Medical Center
New York Presbyterian
New York, New York

John Leonard, MD
Professor of Medicine
Center of Lymphoma and Myeloma
Weill Cornell Medicine
New York, New York

Lauren Pinter-Brown, MD
Professor of Medicine
UC Irvine School of Medicine
Irvine, California

Sarah Rutherford, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Michael Wang, MD
MD Anderson Cancer Center
University of Texas
Houston, Texas

Jennifer Woyach, MD
Associate Professor of Medicine
Division of Hematology
The Ohio State University College of Medicine
Columbus, Ohio


Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.

For questions regarding this educational activity, please call 609-371-1137 or email


This educational activity is specifically designed for hematologists/oncologists, physician assistants, nurse practitioners, nurses, and pharmacists who specialize in hematology, as well as other healthcare providers who care for patients with hematologic malignancies.


After participating in this activity, learners should be better able to:

  • Compare PI3K isoform targets and their relationship to potential adverse events in novel and emerging PI3K inhibitors 
  • Describe the role of PI3K inhibitors in the sequencing of drugs for the treatment of B-NHLs
  • Optimize the treatment of patients with B-NHLs with PI3K inhibitors where appropriate


To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date:September 15, 2021
Expiration Date: September 15, 2022
Estimated Time to Complete: 2.0 hours

There is no fee associated with this activity.


The following companies have provided an educational grant in support of this activity: Bayer, MEI Pharma, and TG Therapeutics



In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 2.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.00 contact hours. 


American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.


This internet enduring, knowledge-based activity (Universal Activity Number:A0006201-9999-21-156-H01-P) has been approved for a maximum of 2.00 contact hours (.2 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 2.00 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.


This activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credits for learning and change.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.


The faculty has reported the following:

Richard Furman: Advisory Board-AbbVie, AstraZeneca, BeiGene, Genentech/Roche, Janssen Pharmaceuticals, Loxo Oncology, Morphosys, Pharmacyclics, Sanofi, TG Therapeutics, Verastem; Consultant-BeiGene, Genentech/Roche; Grant/Research Spport-AstraZeneca, BeiGene, Genentech/Roche, TG Therapeutics; DSMB-Incyte; Speaker-AstraZeneca, Janssen Pharmaceuticals; DSMB-Incyte

Caron A. Jacobson: Advisory Board-AbbVie, Bluebird Bio, Celgene, Kite, Lonza, Novartis; Consultant-Bristol-Myers Squibb, Celgene, Lonza, Novartis; Grant/Research - Kite, Pfizer

Alex Herrera: Consultant- Bristol-Myers Squibb, Genentech, Karyopharm, Merck, Seattle Genetics; Grant/ Research Support- ADCT Therapeutics, AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead Sciences, Kite Pharma, Merck, Seattle Genetics

Manali Kamdar: Consultant-Abbvie, Acerta/ Astrazeneca, Adaptive Biotechnologies, Bristol-Myers Squibb, Karyopharm, Kite Pharma; Grant/ Research support-Genentech, TG Therapeutics; Speakers Bureau-Seattle Genetics

Nicole Lamanna: Advisory Board-AbbVie, Acerta/AstraZenaca, BeiGene, Celgene BMS, Janssen/Pharmacyclics; Grant/Research-AbbVie, Acerta/AstraZeneca, BeiGene, Loxo Oncology/Bayer/Lilly, MingSight, Octapharma, Oncternal Therapeutics, TG Therapeutics, Verastem

John P. Leonard: Consultant-Bristol-Myers Squibb

Lauren Pinter-Brown: Advisory Board-Kyowa Hakko Kirin Pharma; Consultant-Acrotech Biopharma; Speakers Bureau-Acrotech Biopharma

Sarah Rutherford: Advisory Board-Dova, Karyopharm; Grant/Research - Genentech, Karyopharm; Other - Bristol-Myers Squibb, Janssen

Michael Wang- Consultant-Astrazeneca, Bayer, CStone, Genentech, Innocare, Jannsen, Grant/Research support-Acerta, AstraZeneca, BioInvent, Celgene, Innocare, Jannsen; Other financial or material support-Innocare

Jennifer A. Woyach: Advisory Board-AbbVie, AstraZeneca, Janssen, Morphosys, Pharmacyclics, Verastem; Grant/Research-AbbVie, Karyopharm, Loxo Oncology, Verastem; Consultant- AstraZeneca, Janssen, Pharmocyclics


NACCME and Imedex planners and staff include Samantha Conforti, Kelly Jackson, Mary Johnson, Amrita Kabi, Randy Robbin, Greaton Sellers, Shannon Stevenson.

No NACCME or Imedex planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.